Evidence map›Paper›PMID 28812273›Full record

ReviewCurrent topics in behavioral neurosciences

A Precision Medicine Approach to Oxytocin Trials.

Elissar Andari, Rene Hurlemann, Larry J Young

Abstract readReview
In one paragraph

Review in Current topics in behavioral neurosciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Oxytocin does not stand alone.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022
    Article
  14. Article
  15. Article
  16. Oxytocin and the Neurobiology of Prosocial Behavior.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2021
    Review
  17. Early-life oxytocin attenuates the social deficits induced by caesarean-section delivery in the mouse.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  18. Limbic Neuropeptidergic Modulators of Emotion and Their Therapeutic Potential for Anxiety and Post-Traumatic Stress Disorder.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elissar AndariDivision of Behavioral Neuroscience and Psychiatric Disorders, Yerkes National Primate Research Center, Center for Translational Social Neuroscience, Emory University, Atlanta, GA, USA. eandari@gmail.com.
Rene HurlemannDepartment of Psychiatry, Medical Psychology Division, NEMO (Neuromodulation of Emotion) Research Group, University of Bonn, Bonn, Germany.
Larry J YoungDepartment of Psychiatry, Center for Translational Social Neuroscience, Division of Behavioral Neuroscience and Psychiatric Disorders, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
The Impact of Oxytocin on the Neural Representation Social Stimuli P50MH100023 · NIMH · EMORY UNIVERSITY · PI YOUNG, LARRY J · 2013 to 2022
$21.8M
NIH HHS P51 OD011132NIMH NIH HHS P50 MH100023
6 · The paper itself

Abstract

In this chapter, we introduce a new area of social pharmacology that encompasses the study of the role of neuromodulators in modulating a wide range of social behaviors and brain function, with the interplay of genetic and epigenetic factors. There are increasing evidences for the role of the neuropeptide oxytocin in modulating a wide range of social behaviors, in reducing anxiety, and in impacting the social brain network. Oxytocin also promotes social functions in patients with neuropsychiatric disorders, such as autism and reduces anxiety and fear in anxiety disorders. In this chapter, we will emphasize the importance of integrating basic research and clinical human research in determining optimal strategies for drug discoveries for social dysfunctions and anxiety disorders. We will highlight the significance of adopting a precision medicine approach to optimize targeted treatments with oxytocin in neuropsychiatry. Oxytocin effects on social behavior and brain function can vary from one individual to another based on external factors, such as heterogeneity in autism phenotype, childhood experiences, personality, attachment style, and oxytocin receptor polymorphisms. Hence, targeted therapies for subgroups of patients can help alleviating some of the core symptoms and lead to a better future for these patients and their families.

Indexed as

Clinical Trials as TopicAnxiety DisordersAutistic DisorderBrainFearHumansOxytocinPrecision MedicineSocial BehaviorOxytocinAnxiety disordersAutismOxytocinPrecision medicineSocial salience networkTargeted therapies

Identifiers

PMID28812273
PMCPMC5815942

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.